"Q. Question on Zolgensma\u00ae and the intrathecal form. Just could you give us some help on the design of the pivotal trial? Would you look to broaden the age range beyond the 2 to 5 years, which was the original, I suppose, STRONG trial design? And given the thoughts on what's happened to other gene therapies, what do you think the regulators would need in terms of duration, durability to see, particularly in, I suppose, type 2 SMA patients?"